Exemestane vs Rosuvastatin
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Exemestane and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Exemestane Rosuvastatin
Weight 296.40 Da 481.54 Da
Half-life ~24 hours ~19 hours
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Synthetic statin (C22H28FN3O6S-Ca)
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Rosuvastatin
01 Most potent statin available, with LDL reductions of 45-63% depending on dose
02 Long half-life (19 hours) allows flexible once-daily dosing at any time of day
03 Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
04 Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
05 Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
06 Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
07 Proven cardiovascular event and mortality reduction in large-scale clinical trials
08 Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Rosuvastatin
Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
Headache
Nausea and abdominal discomfort
Weakness or fatigue
Constipation or diarrhea
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to rosuvastatin or any excipients
Pregnancy and breastfeeding (Category X -- statins are teratogenic)
Concomitant use with cyclosporine (at all doses of rosuvastatin)
Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg
Research Evidence
Exemestane Rosuvastatin
Status FDA Approved FDA Approved
References 5 studies 4 studies
Latest — 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.